We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Brush Biopsy Test Detects Oral Cancer without Surgery

By LabMedica International staff writers
Posted on 18 Jan 2024
Print article
Image: The cancer detection kit requires less than a minute of gentle brushing to collect a sample (Photo courtesy of Lucia Adami)
Image: The cancer detection kit requires less than a minute of gentle brushing to collect a sample (Photo courtesy of Lucia Adami)

Oral squamous cell carcinoma, the most common type of oral cancer and globally the ninth most prevalent cancer, currently relies on surgical biopsies for diagnosis. This additional referral step poses the risk of losing patients who may not return for follow-up until the cancer has progressed to advanced, more challenging stages. Additionally, surgical biopsies can be problematic as they often collect a mix of cell types, complicating the analysis, and creating the risk of spreading cancerous cells to other parts of the mouth. General blood tests looking for cancer's genetic signals also have limitations, as they do not specify the tumor’s location, preventing quick initiation of treatment after detection. Now, a new test that allows dentists to screen for oral squamous cell carcinoma with a simple brush could early detection of oral cancer without surgery.

The diagnostic kit, created by researchers at the University of Illinois Chicago (Urbana, IL, USA), employs a small brush to gather cells from potential cancerous lesions in the mouth. It operates by detecting tiny segments of genetic material, known as microRNA, which regulate gene expression. Studies conducted by the researchers found a unique expression signature of 40 microRNA sequences that can accurately differentiate between a tumor and normal tissue with more than 90% accuracy. Significantly, their test also successfully works with epithelial cells, the outermost layer in the patient’s mouth. These cells can be quickly and painlessly collected in under a minute by a dentist or nurse using gentle brushing. After collection, the brush is placed in a solution tube and sent to a lab for microRNA analysis, with results being available within days using the current test version.

The brush biopsy test offers several advantages, including specific targeting of the tissue site. The researchers anticipate that this new test will simplify screening, especially in populations that lack regular dental care or are more prone to oral squamous cell carcinoma. For instance, Black men, who experience significantly lower survival rates with this disease compared to other racial groups, could benefit greatly. The potential for using this technology in non-clinical settings opens up opportunities for earlier cancer detection in high-risk groups. Additionally, this approach could eventually help diagnose other oral diseases, each identified by unique microRNA signatures.

“We were the first to observe that brush biopsy samples actually work quite well when you use microRNA,” said Guy Adami of the UIC College of Dentistry. “All you need is a good light and the brushes.”

“There are 600 different diseases that occur in the mouth, and a number of these have already been characterized with microRNAs,” added Dr. Joel Schwartz of the UIC College of Dentistry. “We could use the same approach and really have a profound impact on these kinds of disease.”

Related Links:
University of Illinois Chicago

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.